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Clostridium difﬁcile PCR ribotype 027
in Switzerland
10.1111/j.1469-0691.2008.01989.x
Further to the recent publication in CMI of
a European survey characterising Clostridium
difﬁcile isolates in Europe [1], we would like to
report the occurrence of a small outbreak involv-
ing highly clindamycin-resistant C. difﬁcile iso-
lates belonging to PCR ribotype 027 in
Switzerland.
From June 2006 to July 2007, a two-step algo-
rithm for improved detection of C. difﬁcile in stool
specimens was evaluated [2]. As part of this
study, and for surveillance reasons, all C. difﬁcile
isolates were further characterised with respect to
their phenotypic and genotypic features. Between
October 2006 and May 2007, a cluster of C. difﬁcile
PCR ribotype 027 isolates was detected at
University Hospital Basel (UHBS) and a univer-
sity-afﬁliated geriatric hospital. PCR ribotyping
was performed by the method of Stubbs et al. [3]
and multiple locus variable number tandem
repeat analysis was applied as described previ-
ously [4]. Genes encoding toxins A ⁄B and binary
toxins, as well as the erythromycin resistance
methylase gene (ermB), were detected by PCR
[5–7], and the genotype of the putative negative
regulator gene (tcdC) was determined by sequenc-
ing as described previously [8].
The study revealed the ﬁrst cluster of clinda-
mycin-resistant C. difﬁcile PCR ribotype 027
isolates in Switzerland, possibly imported from
abroad to a Swiss university hospital. The index
patient was a female patient, aged 82 years, who
had been hospitalised in Mallorca, Spain,
6 weeks before diagnosis of C. difﬁcile-associated
disease (CDAD) in Switzerland. However, no
outbreaks caused by type 027 isolates have
been reported in Spain, and type 027 was
not found in a recent surveillance study [1].
Thus, the index patient might have acquired
the strain in Mallorca or from another case of
CDAD in Switzerland. After the index case
was transferred from UHBS to a geriatric
hospital, the strain caused an outbreak affecting
13 patients, but there was no evidence of
extensive spread of this strain at UHBS. In
total, 16 patients with hospital-associated
CDAD were detected between October 2006
and May 2007. The median age of the 16 patients
was 82.5 years (inter-quartile range 78.5–
91.5 years). A moderate-to-severe course was
observed in 43.8% of patients, and the crude
mortality rate was 18.8%. No further cases
involving this strain were observed, despite
intensive epidemiological and laboratory-based
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Fig. 1. Incidenceof laboratory-documentedClostridiumdifﬁcile-associateddisease(CDAD)withpositivestool toxinorpositive
stool culture ⁄ 1000 patient-days at a geriatric hospital (above), and cases of CDAD caused by clindamycin-resistant C. difﬁcile
PCR ribotype 027 isolates at University Hospital Basel and the geriatric hospital between July 2006 andAugust 2007 (below).
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surveillance. Overall, the incidence of CDAD
was low, but increased from 0 to 0.8 cases ⁄
1000 patient-days during March 2007 at the
geriatric hospital (Fig. 1). The incidence at UHBS
did not change over time (data not shown).
All isolates were highly resistant to moxiﬂox-
acin (MIC >32 mg ⁄L), erythromycin (MIC >256
mg ⁄L) and clindamycin (MIC >256 mg ⁄L), but
were susceptible to metronidazole (MIC £0.38
mg ⁄L) and vancomycin (MIC <1.0 mg ⁄L). Genes
for toxins A ⁄B and binary toxins, and ermB, were
detected by PCR in all isolates. The putative
negative regulator gene (tcdC) showed an
18-bp deletion and a single nucleotide deletion
at position 117. Multiple locus variable number
tandem repeat analysis typing revealed a single
cluster of genetically highly related (summed
tandem repeat difference £2) clindamycin-resis-
tant PCR ribotype 027 isolates that differed
considerably from control type 027 isolates. Sim-
ilar small clusters of infection may remain unde-
tected by routine epidemiological surveillance
unless molecular characterisation of strains is
performed. Laboratory-based surveillance sys-
tems should therefore be established, at least for
speciﬁc populations at high risk.
To date, outbreaks of infection caused by
C. difﬁcile type 027 have been associated with
clindamycin-susceptible strains and have been
reported in North America and various countries
in Europe, including the UK, Belgium, The Neth-
erlands and France [1,9]. The emergence of
clindamycin-resistant 027 strains is a new factor
that may result in further spread of this bacterium
in association with antibiotic usage.
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